Logo image of RANI

RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Fundamental Analysis

NASDAQ:RANI - Nasdaq - US7530181004 - Common Stock - Currency: USD

1.08  +0.01 (+0.93%)

After market: 1.1 +0.02 (+1.85%)

Fundamental Rating

1

RANI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. RANI may be in some trouble as it scores bad on both profitability and health. RANI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RANI had negative earnings in the past year.
In the past year RANI has reported a negative cash flow from operations.
In the past 5 years RANI always reported negative net income.
RANI had a negative operating cash flow in each of the past 5 years.
RANI Yearly Net Income VS EBIT VS OCF VS FCFRANI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of RANI (-81.94%) is worse than 72.73% of its industry peers.
The Return On Equity of RANI (-1506.93%) is worse than 82.32% of its industry peers.
Industry RankSector Rank
ROA -81.94%
ROE -1506.93%
ROIC N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
RANI Yearly ROA, ROE, ROICRANI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RANI Yearly Profit, Operating, Gross MarginsRANI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
RANI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RANI has more shares outstanding
Compared to 1 year ago, RANI has a worse debt to assets ratio.
RANI Yearly Shares OutstandingRANI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RANI Yearly Total Debt VS Total AssetsRANI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RANI has an Altman-Z score of -6.98. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
RANI's Altman-Z score of -6.98 is on the low side compared to the rest of the industry. RANI is outperformed by 68.69% of its industry peers.
RANI has a Debt/Equity ratio of 4.83. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 4.83, RANI is doing worse than 82.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.83
Debt/FCF N/A
Altman-Z -6.98
ROIC/WACCN/A
WACC11.58%
RANI Yearly LT Debt VS Equity VS FCFRANI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

RANI has a Current Ratio of 1.50. This is a normal value and indicates that RANI is financially healthy and should not expect problems in meeting its short term obligations.
RANI has a Current ratio of 1.50. This is in the lower half of the industry: RANI underperforms 70.20% of its industry peers.
A Quick Ratio of 1.50 indicates that RANI should not have too much problems paying its short term obligations.
RANI has a worse Quick ratio (1.50) than 62.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
RANI Yearly Current Assets VS Current LiabilitesRANI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

RANI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.30%, which is quite impressive.
The Revenue has been growing slightly by 0.96% on average over the past years.
EPS 1Y (TTM)20.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A

3.2 Future

RANI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.16% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.16%
EPS Next 2Y14.58%
EPS Next 3Y19.39%
EPS Next 5Y13.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RANI Yearly Revenue VS EstimatesRANI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RANI Yearly EPS VS EstimatesRANI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RANI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RANI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RANI Price Earnings VS Forward Price EarningsRANI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RANI Per share dataRANI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as RANI's earnings are expected to grow with 19.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.58%
EPS Next 3Y19.39%

More info and screens

0

5. Dividend

5.1 Amount

RANI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (5/2/2025, 8:19:08 PM)

After market: 1.1 +0.02 (+1.85%)

1.08

+0.01 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners10.85%
Inst Owner Change2.19%
Ins Owners1.5%
Ins Owner Change1.93%
Market Cap62.14M
Analysts86.15
Price Target11.22 (938.89%)
Short Float %9.57%
Short Ratio11.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.59%
Min EPS beat(2)-7.31%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-4.85%
Min EPS beat(4)-39.83%
Max EPS beat(4)19.26%
EPS beat(8)6
Avg EPS beat(8)3.9%
EPS beat(12)10
Avg EPS beat(12)13.98%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.75%
PT rev (3m)-4.35%
EPS NQ rev (1m)-4.27%
EPS NQ rev (3m)3.18%
EPS NY rev (1m)2.07%
EPS NY rev (3m)2.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.45
P/FCF N/A
P/OCF N/A
P/B 31.2
P/tB 31.2
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.02
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.94%
ROE -1506.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 4.83
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.07%
Cap/Sales 26.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z -6.98
F-Score3
WACC11.58%
ROIC/WACCN/A
Cap/Depr(3y)156.71%
Cap/Depr(5y)155.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y9.16%
EPS Next 2Y14.58%
EPS Next 3Y19.39%
EPS Next 5Y13.16%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.88%
EBIT Next 3Y-5.54%
EBIT Next 5Y14.98%
FCF growth 1Y31.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.72%
OCF growth 3YN/A
OCF growth 5YN/A